Amelioration of early radiation effects in oral mucosa (mouse) by intravenous or subcutaneous administration of amifostine

Strahlentherapie und Onkologie

Volumn 182, Issue 10, 2006, Pages 567-575

  Fleischer, Gabriele ^a   Dörr, Wolfgang ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Amifostine; Fractionated irradiation; Mouse model; Mucoprotection; Oral mucositis

Indexed keywords

AMIFOSTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; MOUSE; MOUTH MUCOSA; MOUTH ULCER; NONHUMAN; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; STOMATITIS; THERAPY DELAY; TONGUE; TREATMENT OUTCOME;

AMIFOSTINE; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C3H; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; STOMATITIS; TREATMENT OUTCOME;

EID: 33749247654     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-006-1587-8     Document Type: Article

References (32)

1. Antonadou D, Pepelassi M, Synodinou M, et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2002;52:739-47.
2. Bernier J, Thames HD, Smith CD, et al. Tumor response, mucosal reactions and late effects after conventional and hyperfractionated radiotherapy. Radiother Oncol 1998;47:137-43.
3. Bourhis J, De Crevoisier R, Abdulkarim B, et al. A randomized study of very accelerated radiotherapy with and without amifostine in head and neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2000;46:1105-8.
4. Bourhis J, Rosine D. Radioprotective effect of amifostine in patients with head and neck squamous cell carcinoma. Semin Oncol 2002;29:Suppl 19:61-2.
5. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer [Erratum in: J Clin Oncol 2000;18:4110-1]. J Clin Oncol 2000;18:3339-45.
6. Büntzel J, Glatzel M, Kuttner K, et al. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Semin Radiat Oncol 2002;12:Suppl 1:4-13.
7. Buentzel J, Micke O, Adamietz IA, et al. Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 2006;64:684-91.
8. Cassatt DR, Fazenbaker CA, Bachy CM, et al. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. Int J Radiat Oncol Biol Phys 2005;61:901-7.
9. Cassatt DR, Fazenbaker CA, Kifle G, et al. Subcutaneous administration of amifostine (Ethyol) is equivalent to intravenous administration in a rat mucositis model. Int J Radiat Oncol Biol Phys 2003;57:794-802.
10. Cassatt DR, Fazenbaker CA, Kifle G, et al. Effects of dose and schedule on the efficacy of Ethyol: preclinical studies. Semin Oncol 2003;30:Suppl 18:31-9.
11. Denham JW, Peters LJ, Johansen J, et al. Do acute mucosal reactions lead to consequential late reactions in patients with head and neck cancer? Radiother Oncol 1999;52:157-64.
12. Dietl B, Schafer C, Kolbl O. The prognostic value of time parameters in adjuvant radiotherapy of head and neck cancer. A retrospective analysis of 138 patients. Strahlenther Onkol 2005;181:800-7.
13. Dörr W. Modulation of repopulation processes in oral mucosa: experimental results. Int J Radiat Biol 2003;79:531-7.
14. Dörr W, Breitner A, Kummermehr J. Capacity and kinetics of SLD repair in mouse tongue epithelium. Radiother Oncol 1993;27:36-45.
15. Dörr W, Hamilton CS, Boyd T, et al. Radiation-induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys 2002;52:911-7.
16. Dörr W, Hendry JH. Consequential late effects in normal tissues. Radiother Oncol 2001;61:223-31.
17. Dörr W, Kummermehr J. Accelerated repopulation of mouse tongue epithelium during fractionated irradiations or following single doses. Radiother Oncol 1990;17:249-59.
18. Dörr W, Reichel S, Spekl K. Effects of keratinocyte growth factor (palifermin) administration protocols on oral mucositis (mouse) induced by fractionated irradiation. Radiother Oncol 2005;75:99-105.
19. Dörr W, Spekl K, Farrell CL. Amelioration of acute oral mucositis by keratinocyte growth factor: fractionated irradiation. Int J Radiat Oncol Biol Phys 2002;54:245-51.
20. Epstein JB, Schubert MM. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Huntingt) 2003;17:1767-92.
21. Herrmann T, Baumann M. Prolongation of latency or overall treatment time by unplanned radiation pauses. The clinical importance of compensation. Strahlenther Onkol 2005;181:65-76.
22. Koukourakis MI, Kyrias G, Kakolyris S, et al. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. J Clin Oncol 2000;18:2226-33.
23. Kouloulias VE, Kouvaris JR, Pissakas G, et al. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlenther Onkol 2004;180:557-62.
24. Kuechler A, Dreidax M, Pigorsch SU, et al. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. Strahlenther Onkol 2003;179:493-8.
25. Kutta H, Kampen U, Sagowski C, et al. Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastractural findings. Strahlenther Onkol 2005;181:237-45.
26. Müller AC, Pigorsch S, Beyer C, et al. Radioprotective effect of amifostine in vitro and in vivo measured with the comet assay. Strahlenther Onkol 2004;180:517-25.
27. Saadeh CE. Chemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment. Pharmacotherapy 2005;25:540-4.
28. SAS Institute Inc. SAS/STAT user's guide version 6. Cary: SAS Institute, 1990.
29. Sasse AD, de Oliveira Clark LG, Sasse EC, et al. Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 2006;64:784-91.
30. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy: part 1, pathogenesis and prophylaxis of mucositis. Head Neck 2003;25:1057-70.
31. Suntharalingam M, Jaboin J, Taylor R, et al. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Semin Oncol 2004;31:Suppl 18:2-7.
32. Vacha P, Fehlauer F, Mahlmann B, et al. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 2003;179:385-9.